Immunodeficiency 10 (IMD10) Cell Models for Research

Immunodeficiency 10 (IMD10) is a rare primary immunodeficiency disorder characterized by recurrent infections, autoimmunity, and increased susceptibility to malignancies. The exact prevalence is unknown, but it is estimated to affect fewer than 1 in 1,000,000 individuals worldwide. The condition is caused by mutations in the NFKB1 or NFKB2 genes, which encode subunits of the NF-κB transcription factor complex. Clinical manifestations vary widely, ranging from mild hypogammaglobulinemia to severe combined immunodeficiency. According to the National Cancer Institute (NCI), patients with IMD10 have an increased risk of developing B-cell lymphomas and other cancers, with a 5-year survival rate of approximately 70% for those with malignancies. Early diagnosis and immunoglobulin replacement therapy can improve outcomes, but there is no cure. The rarity and heterogeneity of IMD10 make it a challenging disease to study, highlighting the need for robust experimental models.

IMD10 serves as an excellent model for studying NF-κB signaling, B-cell development, and immune regulation. The disease is caused by mutations in well-defined genes, providing a clear genetic basis for mechanistic studies. Public datasets, such as those from the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas, offer valuable information on NFKB1 and NFKB2 expression across tissues. However, many open questions remain, including the precise molecular mechanisms by which specific mutations lead to distinct clinical phenotypes, and the role of NF-κB in immune cell differentiation. Gene-edited cell models, such as CRISPR knockout and knock-in lines, are essential tools for addressing these questions, as they allow researchers to study the effects of specific mutations in a controlled in vitro environment.

The NF-κB signaling pathway is central to IMD10 pathogenesis. Two major pathways are involved:

1. Canonical NF-κB pathway:

• • Activation by pro-inflammatory cytokines (e.g., TNF-α, IL-1) or pathogen-associated molecular patterns (PAMPs).
• • IκB kinase (IKK) complex phosphorylates IκBα, leading to its ubiquitination and degradation.
• • NF-κB dimers (e.g., p50/RelA) translocate to the nucleus and activate target genes.
• • Mutations in NFKB1 (encoding p50) or NFKB2 (encoding p52) disrupt this pathway, leading to impaired immune responses.

2. Non-canonical NF-κB pathway:

• • Activation by specific ligands (e.g., CD40L, BAFF).
• • NF-κB-inducing kinase (NIK) activates IKKα, which processes p100 to p52.
• • p52/RelB dimers translocate to the nucleus and regulate genes involved in B-cell survival and maturation.
• • Mutations in NFKB2 often affect p100 processing, leading to defective B-cell development.

These pathways are critical for immune cell function, and their dysregulation contributes to the immunodeficiency and lymphomagenesis observed in IMD10.

Data from TCGA and COSMIC databases indicate that these mutations are germline in IMD10, but somatic mutations in NFKB1 and NFKB2 are also found in various cancers, including B-cell lymphomas and multiple myeloma.

The NF-κB pathway interacts with several other signaling networks that are deregulated in IMD10:

• • B-cell receptor (BCR) signaling: NF-κB is a downstream effector of BCR activation, and its impairment leads to defective B-cell proliferation and antibody production.
• • Toll-like receptor (TLR) signaling: TLRs activate NF-κB through MyD88 and TRIF, and mutations in NFKB1/NFKB2 impair innate immune responses.
• • TNF receptor signaling: TNF-α activates NF-κB via TRAF2/5, and dysregulation contributes to chronic inflammation and autoimmunity.
• • PI3K/AKT pathway: Cross-talk between NF-κB and PI3K/AKT influences cell survival and proliferation, and aberrant activation can promote lymphomagenesis.
• • JAK/STAT pathway: NF-κB and JAK/STAT cooperate in cytokine signaling, and their dysregulation affects immune cell differentiation.

These interconnected networks highlight the complexity of IMD10 pathogenesis and the need for comprehensive models to study therapeutic interventions.

Organoids derived from patient-derived induced pluripotent stem cells (iPSCs) offer a more physiologically relevant model, as they can recapitulate the three-dimensional architecture of lymphoid tissues and allow for the study of cell-cell interactions. However, organoids are more complex to maintain and are not yet widely used for IMD10 research.

• • Patient-derived xenografts (PDX): Immunodeficient mice engrafted with patient-derived tumor cells or immune cells. Useful for studying tumor biology and drug responses.
• • Genetically engineered mouse models (GEMM): Mice with targeted mutations in Nfkb1 or Nfkb2. For example, Nfkb1 knockout mice exhibit defective B-cell responses and increased susceptibility to infections.
• • Induced models: Conditional knockout mice using Cre-lox systems to delete Nfkb1 or Nfkb2 in specific cell types (e.g., B cells or T cells). These models allow for temporal and spatial control of gene deletion.

Animal models are valuable for in vivo studies, but they are time-consuming and costly. Gene-edited cell models provide a faster and more cost-effective alternative for initial screening and mechanistic studies.

CRISPR-based gene editing has revolutionized the creation of isogenic cell models for IMD10. Commercially available, sequence-verified cell lines with specific NFKB1 or NFKB2 mutations are now accessible, enabling researchers to study the functional consequences of these mutations in a controlled background.

• • Examples of gene-edited models include:
• • NFKB1 knockout cell lines: Generated by introducing frameshift mutations in the NFKB1 gene, resulting in loss of p50 protein. These lines are useful for studying the role of p50 in B-cell signaling and immune responses.
• • NFKB2 knock-in cell lines: Engineered to carry specific patient-derived mutations, such as the p.Arg853* nonsense mutation, which leads to a truncated p100 protein. These lines allow for the study of dominant-negative effects and impaired p100 processing.

These gene-edited models are essential for functional genomics, drug screening, and biomarker discovery, as they provide a reproducible and scalable platform for experiments.

Gene-edited cell lines are powerful tools for functional genomics. For example, NFKB1 knockout cell lines can be used to identify genes that are regulated by p50, either through transcriptomic analysis (RNA-seq) or chromatin immunoprecipitation sequencing (ChIP-seq). Similarly, NFKB2 knock-in lines can be used to study the impact of specific mutations on downstream signaling pathways. By comparing wild-type and mutant lines, researchers can pinpoint the molecular mechanisms underlying IMD10 and identify potential therapeutic targets.

Isogenic cell line pairs (wild-type vs. mutant) are ideal for drug screening. For instance, NFKB2 mutant cells can be used to test the efficacy of NF-κB pathway inhibitors, such as IKK inhibitors or proteasome inhibitors. These screens can identify compounds that selectively kill mutant cells while sparing wild-type cells, providing a therapeutic window. Additionally, gene-edited lines can be used to model drug resistance by exposing them to increasing concentrations of a drug and selecting for resistant clones. This approach can reveal resistance mechanisms and guide combination therapy strategies.

CRISPR-based synthetic lethality screens can identify genes that are essential for the survival of NFKB1/NFKB2 mutant cells but not wild-type cells. These synthetic lethal interactions can serve as biomarkers for patient stratification and as targets for novel therapeutics. For example, a screen using NFKB1 knockout cells might reveal a dependency on the alternative NF-κB pathway, suggesting that inhibitors of NIK or IKKα could be effective in treating IMD10-associated tumors. Gene-edited models thus accelerate the discovery of biomarkers and therapeutic targets.